SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:db1f46c3-1b37-4cce-88f1-36d1124d2859"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:db1f46c3-1b37-4cce-88f1-36d1124d2859" > Perspectives on a W...

  • Bakker, ElisabethUniversity Medical Center Groningen (författare)

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021-05-04
  • Frontiers Media SA,2021

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:db1f46c3-1b37-4cce-88f1-36d1124d2859
  • https://lup.lub.lu.se/record/db1f46c3-1b37-4cce-88f1-36d1124d2859URI
  • https://doi.org/10.3389/fphar.2021.662642DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Aim: This study aimed to identify from different stakeholders the benefits and obstacles of implementing precision medicine in diabetic kidney disease (DKD) and to build consensus about a way forward in order to treat, prevent, or even reverse this disease. Methods: As part of an ongoing effort of moving implementation of precision medicine in DKD forward, a two-day consensus-building meeting was organized with different stakeholders involved in drug development and patient care in DKD, including patients, patient representatives, pharmaceutical industry, regulatory agencies representatives, health technology assessors, healthcare professionals, basic scientists, and clinical academic researchers. The meeting consisted of plenary presentations and discussions, and small group break-out sessions. Discussion topics were based on a symposium, focus groups and literature search. Benefits, obstacles and potential solutions toward implementing precision medicine were discussed. Results from the break-out sessions were presented in plenary and formed the basis of a broad consensus discussion to reach final conclusions. Throughout the meeting, participants answered several statement and open-ended questions on their mobile device, using a real-time online survey tool. Answers to the statement questions were analyzed descriptively. Results of the open-ended survey questions, the break-out sessions and the consensus discussion were analyzed qualitatively. Results and conclusion: Seventy-one participants from 26 countries attended the consensus-building meeting in Amsterdam, April 2019. During the opening plenary on the first day, the participants agreed with the statement that precision medicine is the way forward in DKD (n = 57, median 90, IQR [75–100]). Lack of efficient tools for implementation in practice and generating robust data were identified as significant obstacles. The identified benefits, e.g., improvement of the benefit-risk ratio of treatment, offer substantive incentives to find solutions for the identified obstacles. Earlier and increased multi-stakeholder collaboration and specific training may provide solutions to alter clinical and regulatory guidelines that lie at the basis of both obstacles and solutions. At the end of the second day, the opinion of the participants toward precision medicine in DKD was somewhat more nuanced (n = 45, median 83, IQR [70–92]) and they concluded that precision medicine is an important way forward in improving the treatment of patients with DKD.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Mol, Peter G.M.European Medicines Agency (EMA),Medicines Evaluation Board, Utrecht,University Medical Center Groningen (författare)
  • Nabais, JoãoUniversity of Évora,APDP - Associação Protectora dos Diabéticos de Portugal (författare)
  • Vetter, ThorstenEuropean Medicines Agency (EMA) (författare)
  • Kretzler, MatthiasUniversity of Michigan Health System (författare)
  • Nolan, John J.Trinity College Dublin (författare)
  • Mayer, GertMedical University of Innsbruck (författare)
  • Sundgren, Anna K.AstraZeneca, UK (författare)
  • Heerspink, Hiddo J.L.University Medical Center Groningen (författare)
  • Schiel, AnjaEuropean Medicines Agency (EMA) (författare)
  • de Vries, Sieta T.University Medical Center Groningen (författare)
  • Gomez, Maria F.Lund University,Lunds universitet,Diabetiska komplikationer,Forskargrupper vid Lunds universitet,Diabetic Complications,Lund University Research Groups(Swepub:lu)mphy-mgo (författare)
  • Schulze, FriedrichBoehringer Ingelheim GmbH (författare)
  • de Zeeuw, DickUniversity Medical Center Groningen (författare)
  • Pena, Michelle J.University Medical Center Groningen (författare)
  • University Medical Center GroningenEuropean Medicines Agency (EMA) (creator_code:org_t)
  • BEAt-DKD Consortium

Sammanhörande titlar

  • Ingår i:Frontiers in Pharmacology: Frontiers Media SA121663-9812

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy